EGFR and colorectal carcinoma: In the present study, our differential expression and survival analyses indicated that c-MET/EGFR can be an effective biomarker for CRC progression, immune infiltration, CAF infiltration, and poor prognoses, and thus can serve as attractive targets for exploring the development of chemotherapeutic agents against CRC.